无创生物标志物模型客观评估特应性皮炎严重程度并检测亚临床炎症
本研究为横断面观察性研究(NCT04295824),纳入80名11-60岁受试者(健康对照及轻至重度特应性皮炎患者),采集32种无创至有创生物标志物。多变量模型基于无创OCT影像生物标志物预测局部AD严重程度(r=0.82),全局严重程度和患者报告结局预测精度高(r=0.95和0.76);多模态分类模型区分健康与临床非皮损AD皮肤性能优异(AUC=0.94,95%CI 0.88-0.98)。
要点
- 无创OCT影像生物标志物模型可客观预测AD局部严重程度(r=0.82)。
- 多模态模型能检测临床非皮损皮肤的亚临床炎症(AUC=0.94)。
- 无创客观工具可补充标准评估,优化临床工作流和治疗策略。
核心结论
- 无创多模态生物标志物模型可可靠评估AD严重程度并检测传统评分忽略的亚临床活动。
研究设计与样本
- 横断面观察性研究(NCT04295824),纳入80名11-60岁受试者,包括健康对照和轻至重度AD患者。
- 采集32种生物标志物,涵盖结构(如OCT)、生物物理(如TEWL)、分子(如FTIR)和代谢物(皮肤细胞和血液)标志物。
- 使用Lasso回归构建AD严重程度预测模型和临床非皮损皮肤亚临床疾病分类模型。
主要发现
- 由无创OCT影像衍生生物标志物组成的多变量模型预测局部AD严重程度准确性良好(r=0.82)。
- 全局严重程度和患者报告结局也可高精度预测(r分别为0.95和0.76),模型提供了AD范围信息。
- 多模态分类模型区分健康与临床非皮损AD皮肤性能优异(AUC=0.94,95%CI:0.88-0.98),提示对亚临床炎症敏感。
临床怎么用
- 无创OCT等客观工具可整合至临床工作流,补充标准评估并改进治疗策略。
- 这些方法为临床试验和实践中疾病活动提供更客观的评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Atopic dermatitis (AD) is a chronic, fluctuating inflammatory skin disease in which severity assessment relies on subjective clinical scoring. However, these approaches do not capture subclinical inflammation that may precede disease worsening or follow disease resolution. Furthermore, comprehensive research typically requires invasive methods such as skin biopsy, limiting routine use. OBJECTIVES: This study developed and evaluated non-invasive, multimodal biomarker models to objectively assess AD severity and detect subclinical disease activity. METHODS: We conducted a cross-sectional observational study (NCT04295824) involving 80 participants aged 11-60, including healthy controls and individuals with mild to severe AD. Clinical severity and patient-reported outcomes were assessed, and 32 biomarkers spanning invasive to non-invasive modalities were collected from lesional and non-lesional skin. These included structural (e.g. optical coherence tomography), biophysical (e.g. transepidermal water loss), molecular (e.g. Fourier-transform infrared spectroscopy) and metabolite (biomarkers measured in skin cells and blood) markers. Lasso regression was used to build predictive models of AD severity and classify subclinical disease in clinically non-lesional skin. RESULTS: A multivariable model comprised of non-invasive OCT imaging derived biomarkers predicted local AD severity outcomes with good accuracy (r=0.82). Global severity and patient reported outcomes could also be predicted with high accuracy (r=0.95,0.76 respectively), providing information regarding the extent of AD was provided to the model. Multimodal classification models distinguished healthy from clinically non-lesional AD skin with excellent performance (AUC = 0.94, 95% CI: 0.88-0.98), suggesting sensitivity to subclinical inflammation. CONCLUSIONS: A comprehensive, patient-centered skin assessment approach can reliably determine AD severity and detect subclinical activity that traditional scoring methods may overlook. Robust OCT-derived metrics highlight the potential of integrating non-invasive, objective tools into clinical workflows to complement standard evaluations and improve treatment strategies. These methods also offer a more objective assessment of disease activity in clinical trials and practice.
引用
- Byers RA, Andrew PV, Sahib S, et al. Non-Invasive Biomarker Models for Objective Severity Assessment and Detection of Subclinical Inflammation in Non-Lesional Atopic Dermatitis. Br J Dermatol. 2026. PMID: 42619512. doi:10.1093/bjd/ljag343
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。